Latest Antiandrogens Stories

Note: This release corresponds to ASCO abstracts 5014, 5004, 5009, 5010, 5013, 5037, 5059, 9617, 9618, 5059, 8502, 7130, 8619, 8613, 8614, 7014, 7056, 7057, 8512 and electronic publication e17510 RARITAN, N.J., May 15, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen Oncology compounds have been selected for presentation at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May...

ORLANDO, Fla., Feb. 12, 2013 /PRNewswire/ -- Janssen Research & Development, LLC [Janssen] announced today updated results showing ZYTIGA(®) (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer. The Phase 3, randomized, multicenter, placebo-controlled study (COU-AA-302) also demonstrated...

RARITAN, N.J., Dec. 12, 2012 /PRNewswire/ -- Janssen Research & Development, LLC announced today that results from analyses of COU-AA-302, a Phase 3, randomized, placebo-controlled study of ZYTIGA(® )(abiraterone acetate) plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) prior to chemotherapy, have been published online in The New England Journal of Medicine. This study was the basis of Monday's U.S. Food and Drug Administration (FDA)...

HORSHAM, Pa., Dec. 10, 2012 /PRNewswire/ -- Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA(®) (abiraterone acetate). Until now, ZYTIGA with prednisone has only been approved to treat men with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel. With this approval, ZYTIGA, in combination with prednisone, may now be used...

SAN DIEGO, Oct. 1, 2012 /PRNewswire/ -- Aragon Pharmaceuticals Inc., a leader in developing drugs for hormone driven cancers, announced new data from an ongoing, open-label, multicenter Phase II study of ARN-509, the company's 2nd generation androgen receptor antagonist, demonstrating promising results of ARN-509 in three separate patient populations with castration resistant prostate cancer (CRPC). Data were presented at the European Society for Medical Oncology 2012 Annual...

VIENNA, Sept. 30, 2012 /PRNewswire/ -- Additional data from pre-specified interim analyses of COU-AA-302, a Phase 3, randomized, placebo-controlled study, suggested ZYTIGA(®) (abiraterone acetate) plus prednisone, compared to placebo plus prednisone, delayed pain progression and functional decline in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients whose disease progressed after androgen deprivation therapy and anti-androgens....

RARITAN, N.J., Aug. 29, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA(®) (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy....

Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4. If confirmed, these data mean that levels of hormones, specifically adrenal androgens, may provide physicians with another way to predict the efficacy of therapy in patients with...

Androgen suppression – the inhibition of testosterone and other male hormones – is a routine therapy for prostate cancer. Unfortunately, it can dramatically reduce the quality of patients' sex lives and, more importantly, lead to cancer recurrence in a more deadly androgen-independent form. A new paper combining mathematical modeling with clinical data validates a different approach: cycling patients on and off treatment. Such intermittent androgen suppression alleviates most unwanted...

Increasing access to mifepristone to improve women's reproductive health choices LONDON, Feb. 9, 2012 /PRNewswire-USNewswire/ -- WomanCare Global announced today that mifepristone has been added to their reproductive healthcare portfolio. Through an agreement with Linepharma, WomanCare Global will provide sales, marketing, provider training and distribution of mifepristone in seven European and seven African countries. (Logo:...